Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6298201 | 0.84 | PIN1 (0.47) | SLC15A1LMNASMN1; SMN2 | |
| SCHEMBL27565891 | 0.84 | PIN1 (0.47) | SLC15A1LMNASMN1; SMN2 | |
| SCHEMBL5966898 | 0.80 | SMN1; SMN2 (0.40) | SLC15A1SMN1; SMN2 | |
| SCHEMBL10423913 | 0.80 | AKT1 (0.42) | CTSLCTSBCTSSAKT1HDAC3 | |
| SCHEMBL11407459 | 0.79 | MME (0.45) | CTSLCTSBCTSS | |
| SCHEMBL8859231 | 0.78 | LMNA (0.58) | HDAC1LMNAHPGD | |
| SCHEMBL19567145 | 0.78 | CTSL (0.55) | CTSLCTSBCTSSAKT1HDAC3 | |
| SCHEMBL11407462 | 0.77 | CTSL (0.44) | CTSLCTSBCTSSAKT1HDAC3 | |
| SCHEMBL20187564 | 0.76 | AKT1 (0.60) | CTSLCTSBCTSSAKT1HDAC3 | |
| SCHEMBL782348 | 0.76 | AKT1 (0.55) | CTSLCTSBCTSSAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233886-B1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | OREAL (FR) | 2020-02-26 | — | — | EP | disclosed |
| US-10098827-B2 | Compounds in the family of N-acylamino-amides, compositions comprising them, and uses | L'OREAL (FR) | 2018-10-16 | — | — | US | disclosed |
| US-20170360667-A1 | NEW COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'OREAL (FR) | 2017-12-21 | — | — | US | disclosed |
| EP-3233886-A1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'Oréal (FR) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096804-A1 | COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | L'OREAL (FR) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360667-A1 | NEW COMPOUNDS IN THE FAMILY OF N-ACYLAMINO-AMIDES, COMPOSITIONS COMPRISING THEM, AND USES | H1-0, CRY1, CCNA1 | CTSL 2977/4885CTSB 1781/4885CTSS 1751/4885 |
| US-10098827-B2 | Compounds in the family of N-acylamino-amides, compositions comprising them, and uses | CRY1, H1-0, C1R | CTSL 3336/4885CTSB 1850/4885CTSS 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.